Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Orthofix Medical Inc.OFIX · Entity 1975 | President, Global Spine | March 04, 2026 | March 06, 2026 |
| Pacira BioSciences, Inc.PCRX · Entity 4928 | President, Rest of World | June 06, 2023 | June 08, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Orthofix Medical Inc.
Report date March 04, 2026 · Filed March 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,348 |
Last balance in matching sequence
After 2026-03-05 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-03-04 · Sale · Disposed 1,080 · Balance 26,401 F1: Represents the number of shares of common stock sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units, pursuant to a pre-existing sell-to-cover requirement previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). Such sale was made without the exercise of any discretion by the reporting person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.80 to $13.03, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4. F3: Includes 19,417 previously reported restricted stock units. Row 2 · 2026-03-05 · Sale · Disposed 1,053 · Balance 25,348 F1: Represents the number of shares of common stock sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units, pursuant to a pre-existing sell-to-cover requirement previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). Such sale was made without the exercise of any discretion by the reporting person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.48 to $12.72, inclusive. F3: Includes 19,417 previously reported restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of common stock sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units, pursuant to a pre-existing sell-to-cover requirement previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). Such sale was made without the exercise of any discretion by the reporting person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.80 to $13.03, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4.
F3: Includes 19,417 previously reported restricted stock units.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.48 to $12.72, inclusive.
Pacira BioSciences, Inc.
Report date June 06, 2023 · Filed June 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,225 |
Ending reported balance
After 2023-06-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-06-06 · Sale · Disposed 1,054 · Balance 30,324 F1: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Row 2 · 2023-06-07 · Sale · Disposed 1,099 · Balance 29,225 F1: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 05, 2026 Filed Mar 6, 2026 21:14 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | SaleCommon Stock | 1,053 | $12.55 | $13,215.99 |
DisclosureSEC source: 0001193125-26-096553 · ownership.xml · nonDerivative · entry 2 REINHARDT MAX · CIK 0001780058 · President, Global Spine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,348 F1 · kind: Represents the number of shares of common stock sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units, pursuant to a pre-existing sell-to-cover requirement previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). Such sale was made without the exercise of any discretion by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.48 to $12.72, inclusive. F3 · balance_after: Includes 19,417 previously reported restricted stock units. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:14 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | SaleCommon Stock | 1,080 | $12.92 | $13,949.60 |
DisclosureSEC source: 0001193125-26-096553 · ownership.xml · nonDerivative · entry 1 REINHARDT MAX · CIK 0001780058 · President, Global Spine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,401 F1 · kind: Represents the number of shares of common stock sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units, pursuant to a pre-existing sell-to-cover requirement previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). Such sale was made without the exercise of any discretion by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.80 to $13.03, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4. F3 · balance_after: Includes 19,417 previously reported restricted stock units. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:10 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | SaleCommon Stock | 1,643 | $11.64 | $19,124.52 |
DisclosureSEC source: 0000950170-25-086178 · ownership.xml · nonDerivative · entry 1 REINHARDT MAX · CIK 0001780058 · President, Global Spine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,481 F1 · kind: Represents the number of shares of common stock sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units, pursuant to a pre-existing sell-to-cover requirement previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). Such sale was made without the exercise of any discretion by the reporting person. F2 · balance_after: Includes 24,324 previously reported restricted stock units. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:21 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantEmployee Stock Option (Right to Buy) · Derivative | 34,924 | $0.00 Strike: $16.98 | $0.00 |
DisclosureSEC source: 0000950170-25-033632 · ownership.xml · derivative · entry 2 REINHARDT MAX · CIK 0001780058 · President, Global Spine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,924 Underlying: Common Stock · 34,924 shares Expires 2032-03-03 F3 · derivative.exercise_date: The options vest and become exercisable with respect to one-third (1/3rd) of the shares covered thereby on the first, second and third anniversary of the Grant Date. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:21 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantCommon Stock | 14,723 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-033632 · ownership.xml · nonDerivative · entry 1 REINHARDT MAX · CIK 0001780058 · President, Global Spine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,124 F1 · shares: The restricted stock units vest with respect to one-third (1/3rd) of the shares of stock covered hereby on each of the first, second and third anniversaries of the Grant Date. F2 · balance_after: Includes 14,401 previously reported restricted stock units. Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 20:35 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantEmployee Stock Option (Right to Buy) · Derivative | 190,731 | $0.00 Strike: $13.02 | $0.00 |
DisclosureSEC source: 0000950170-24-072505 · ownership.xml · derivative · entry 2 REINHARDT MAX · CIK 0001780058 · President, Global Spine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,731 Underlying: Common Stock · 190,731 shares Expires 2031-06-10 F2 · derivative.exercise_date: 33,103 of the stock options vest upon achievement of both service- and performance-based criteria, whichever is the later of (a) the date certain service-based conditions are met (which will be met over three years) and (b) the date that the average closing price of the Company's common stock over a one-month calendar period has been equal to or great than 150% of the closing price of the Company's common stock on the grant date. The remaining 157,628 stock options vest on the third anniversary of the grant date. Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 20:35 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantCommon Stock | 14,401 | $13.02 | $187,501.02 |
DisclosureSEC source: 0000950170-24-072505 · ownership.xml · nonDerivative · entry 1 REINHARDT MAX · CIK 0001780058 · President, Global Spine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,401 F1 · shares: The restricted stock units vest with respect to one-third (1/3rd) of the shares of stock covered hereby on each of the first, second and third anniversaries of the Grant Date. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 01:28 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,099 | $37.87 | $41,613.64 |
DisclosureSEC source: 0001209191-23-035260 · doc4.xml · nonDerivative · entry 2 REINHARDT MAX · CIK 0001780058 · President, Rest of World 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,225 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 01:28 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,054 | $38.99 | $41,096.51 |
DisclosureSEC source: 0001209191-23-035260 · doc4.xml · nonDerivative · entry 1 REINHARDT MAX · CIK 0001780058 · President, Rest of World 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,324 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document |
| October 07, 2022 Filed Oct 11, 2022 20:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,380 | $58.00 | $80,040.00 |
DisclosureSEC source: 0001209191-22-053275 · doc4.xml · nonDerivative · entry 1 REINHARDT MAX · CIK 0001780058 · President, Rest of World 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,378 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · balance_after: Includes 408 shares of common stock acquired under the issuer's employee stock purchase plan in June 2022. Read SEC document |
| June 08, 2022 Filed Jun 8, 2022 23:40 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 19,900 | $0.00 Strike: $59.39 | $0.00 |
DisclosureSEC source: 0001209191-22-035229 · doc4.xml · derivative · entry 4 REINHARDT MAX · CIK 0001780058 · President, Rest of World 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,900 Underlying: Common Stock · 19,900 shares Expires 2032-06-08 F4 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 08, 2022 Filed Jun 8, 2022 23:40 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 7,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-035229 · doc4.xml · nonDerivative · entry 3 REINHARDT MAX · CIK 0001780058 · President, Rest of World 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,250 F3 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2023, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 07, 2022 Filed Jun 8, 2022 23:40 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,433 | $62.00 | $150,846.00 |
DisclosureSEC source: 0001209191-22-035229 · doc4.xml · nonDerivative · entry 2 REINHARDT MAX · CIK 0001780058 · President, Rest of World 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,400 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 23:40 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,817 | $61.37 | $172,890.56 |
DisclosureSEC source: 0001209191-22-035229 · doc4.xml · nonDerivative · entry 1 REINHARDT MAX · CIK 0001780058 · President, Rest of World 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,833 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document |
| April 21, 2022 Filed Apr 25, 2022 20:12 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $42.54 | $0.00 |
DisclosureSEC source: 0001209191-22-025516 · doc4.xml · derivative · entry 3 REINHARDT MAX · CIK 0001780058 · President, Rest of World 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 12,500 shares Expires 2029-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| April 21, 2022 Filed Apr 25, 2022 20:12 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 9,824 | $73.25 | $719,647.30 |
DisclosureSEC source: 0001209191-22-025516 · doc4.xml · nonDerivative · entry 2 REINHARDT MAX · CIK 0001780058 · President, Rest of World 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,650 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · shares: Represents shares sold by the reporting person to cover the (i) exercise price of stock options and (ii) tax obligations due upon the exercise of such stock options. Read SEC document |
| April 21, 2022 Filed Apr 25, 2022 20:12 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 12,500 | $42.54 | $531,750.00 |
DisclosureSEC source: 0001209191-22-025516 · doc4.xml · nonDerivative · entry 1 REINHARDT MAX · CIK 0001780058 · President, Rest of World 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| April 20, 2022 Filed Apr 21, 2022 00:25 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $42.54 | $0.00 |
DisclosureSEC source: 0001209191-22-025120 · doc4.xml · derivative · entry 9 REINHARDT MAX · CIK 0001780058 · President, Rest of World 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 12,500 shares Expires 2029-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| April 20, 2022 Filed Apr 21, 2022 00:25 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 9,764 | $73.99 | $722,438.36 |
DisclosureSEC source: 0001209191-22-025120 · doc4.xml · nonDerivative · entry 6 REINHARDT MAX · CIK 0001780058 · President, Rest of World 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,974 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| April 20, 2022 Filed Apr 21, 2022 00:25 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 12,500 | $42.54 | $531,750.00 |
DisclosureSEC source: 0001209191-22-025120 · doc4.xml · nonDerivative · entry 5 REINHARDT MAX · CIK 0001780058 · President, Rest of World 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,738 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| April 19, 2022 Filed Apr 21, 2022 00:25 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $42.54 | $0.00 |
DisclosureSEC source: 0001209191-22-025120 · doc4.xml · derivative · entry 8 REINHARDT MAX · CIK 0001780058 · President, Rest of World 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 12,500 shares Expires 2029-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| April 19, 2022 Filed Apr 21, 2022 00:25 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 9,321 | $72.25 | $673,442.25 |
DisclosureSEC source: 0001209191-22-025120 · doc4.xml · nonDerivative · entry 4 REINHARDT MAX · CIK 0001780058 · President, Rest of World 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,238 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · shares: Represents shares sold by the reporting person to cover the (i) exercise price of stock options and (ii) tax obligations due upon the exercise of such stock options. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.01 to $72.55, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 19, 2022 Filed Apr 21, 2022 00:25 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 12,500 | $42.54 | $531,750.00 |
DisclosureSEC source: 0001209191-22-025120 · doc4.xml · nonDerivative · entry 3 REINHARDT MAX · CIK 0001780058 · President, Rest of World 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,559 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| April 18, 2022 Filed Apr 21, 2022 00:25 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $42.54 | $0.00 |
DisclosureSEC source: 0001209191-22-025120 · doc4.xml · derivative · entry 7 REINHARDT MAX · CIK 0001780058 · President, Rest of World 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,500 Underlying: Common Stock · 12,500 shares Expires 2029-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| April 18, 2022 Filed Apr 21, 2022 00:25 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 8,941 | $73.55 | $657,610.55 |
DisclosureSEC source: 0001209191-22-025120 · doc4.xml · nonDerivative · entry 2 REINHARDT MAX · CIK 0001780058 · President, Rest of World 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,059 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · shares: Represents shares sold by the reporting person to cover the (i) exercise price of stock options and (ii) tax obligations due upon the exercise of such stock options. Read SEC document |
| April 18, 2022 Filed Apr 21, 2022 00:25 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 12,500 | $42.54 | $531,750.00 |
DisclosureSEC source: 0001209191-22-025120 · doc4.xml · nonDerivative · entry 1 REINHARDT MAX · CIK 0001780058 · President, Rest of World 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| July 02, 2021 Filed Jul 6, 2021 22:14 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 421 | $59.76 | $25,158.96 |
DisclosureSEC source: 0001209191-21-045622 · doc4.xml · nonDerivative · entry 1 REINHARDT MAX · CIK 0001780058 · President, Rest of World 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · balance_after: Includes 421 shares of common stock acquired under the issuer's employee stock purchase plan in June 2021. Read SEC document |
| June 09, 2021 Filed Jun 12, 2021 00:40 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $60.96 | $0.00 |
DisclosureSEC source: 0001209191-21-040094 · doc4.xml · derivative · entry 2 REINHARDT MAX · CIK 0001780058 · President, Rest of World 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2031-06-09 F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 09, 2021 Filed Jun 12, 2021 00:40 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040094 · doc4.xml · nonDerivative · entry 1 REINHARDT MAX · CIK 0001780058 · President, Rest of World 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2022, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 07, 2021 Filed Jun 8, 2021 20:16 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,278 | $60.50 | $137,819.00 |
DisclosureSEC source: 0001209191-21-038889 · doc4.xml · nonDerivative · entry 2 REINHARDT MAX · CIK 0001780058 · President, Rest of World 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 20:16 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,222 | $61.04 | $74,587.21 |
DisclosureSEC source: 0001209191-21-038889 · doc4.xml · nonDerivative · entry 1 REINHARDT MAX · CIK 0001780058 · President, Rest of World 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,778 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 21:39 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 110 | $60.81 | $6,689.10 |
DisclosureSEC source: 0001209191-21-002722 · doc4.xml · nonDerivative · entry 1 REINHARDT MAX · CIK 0001780058 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · balance_after: Includes 110 shares of common stock acquired under the issuer's employee stock purchase plan in December 2020. Read SEC document |
| November 13, 2020 Filed Nov 17, 2020 22:28 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $42.54 | $0.00 |
DisclosureSEC source: 0001209191-20-058818 · doc4.xml · derivative · entry 4 REINHARDT MAX · CIK 0001780058 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 25,000 shares Expires 2029-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| November 13, 2020 Filed Nov 17, 2020 22:28 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 21,000 | $63.51 | $1,333,710.00 |
DisclosureSEC source: 0001209191-20-058818 · doc4.xml · nonDerivative · entry 3 REINHARDT MAX · CIK 0001780058 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.005 to $63.990, inclusive. Read SEC document |
| November 13, 2020 Filed Nov 17, 2020 22:28 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 4,000 | $62.67 | $250,680.00 |
DisclosureSEC source: 0001209191-20-058818 · doc4.xml · nonDerivative · entry 2 REINHARDT MAX · CIK 0001780058 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.000 to $62.995, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3. Read SEC document |
| November 13, 2020 Filed Nov 17, 2020 22:28 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 25,000 | $42.54 | $1,063,500.00 |
DisclosureSEC source: 0001209191-20-058818 · doc4.xml · nonDerivative · entry 1 REINHARDT MAX · CIK 0001780058 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| September 17, 2020 Filed Sep 21, 2020 22:23 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $42.54 | $0.00 |
DisclosureSEC source: 0001209191-20-051357 · doc4.xml · derivative · entry 4 REINHARDT MAX · CIK 0001780058 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 25,000 shares Expires 2029-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| September 17, 2020 Filed Sep 21, 2020 22:23 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,888 | $60.26 | $174,030.88 |
DisclosureSEC source: 0001209191-20-051357 · doc4.xml · nonDerivative · entry 3 REINHARDT MAX · CIK 0001780058 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.180 to $60.400, inclusive. Read SEC document |
| September 17, 2020 Filed Sep 21, 2020 22:23 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 22,532 | $59.75 | $1,346,287.00 |
DisclosureSEC source: 0001209191-20-051357 · doc4.xml · nonDerivative · entry 2 REINHARDT MAX · CIK 0001780058 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,888 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.165 to $60.160, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 4. F3 · balance_after: Includes 420 shares of common stock acquired under the issuer's employee stock purchase plan in June 2020. Read SEC document |
| September 17, 2020 Filed Sep 21, 2020 22:23 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 25,000 | $42.54 | $1,063,500.00 |
DisclosureSEC source: 0001209191-20-051357 · doc4.xml · nonDerivative · entry 1 REINHARDT MAX · CIK 0001780058 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 22:31 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $47.65 | $0.00 |
DisclosureSEC source: 0001209191-20-036048 · doc4.xml · derivative · entry 2 REINHARDT MAX · CIK 0001780058 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-06-09 F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 22:31 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036048 · doc4.xml · nonDerivative · entry 1 REINHARDT MAX · CIK 0001780058 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2021, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 17:20 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $42.54 | $0.00 |
DisclosureSEC source: 0001209191-19-040764 · doc4.xml · derivative · entry 1 REINHARDT MAX · CIK 0001780058 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2029-07-02 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.